Table 4 Targeting CD33: T-cell-recruiting bispecific antibodies.
From: T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
Clinicaltrials.gov identifier | AML target antigen | Study name | Drug name | Combination therapy? | Clinical phase | Indication | Primary end point | Estimated enrollment | Estimated completion date | Sponsor | Country | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT02520427 | CD33 | A phase I first-in-human study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 330 administered as continuous intravenous infusion | AMG 330 | No | I | R/R AML | DLT, toxicity | 50 | 2021 | Amgen | USA, Germany, Netherlands | Recruiting |
NCT03224819 | CD33 | Study of AMG 673 in subjects with R/R AML | AMG 673 | No | I | R/R AML | DLT, toxicity | 50 | 2022 | Amgen | USA, Australia, Germany | Recruiting |
NCT03516760 | CD33 | A multicenter, open-label, dose-escalating, phase I trial with GEM333, CD33-targeted bispecific antibody-engaging T cells | GEM333 | No | I | R/R AML | MTD, DLT, toxicity | 33 | 2019 | GEMoab Monoclonals | Germany | Recruiting |
NCT03144245 | CD33 | A phase I, first-in-human, open-label, dose-escalating study of AMV564, a CD33 x CD3 tandem diabody | AMV564 | No | I | R/R AML | DLT, toxicity | 50 | 2020 | Amphivena | USA | Recruiting |
NCT03915379 | CD33 | A study of JNJ-67571244 in participants with R/R AML or MDS | JNJ-67571244 | No | I | R/R AML | DLT, toxicity, ORR | 90 | 2021 | Janssen Research and Development, LLC | USA, Germany, Spain | Recruiting |
NCT03647800 | CD33 | Study of APVO436 in Patients with AML or MDS | APVO436 | No | I | R/R AML | DLT | 108 | 2020 | Aptevo Research and Development LLC | USA | Recruiting |
